Japanese pharmaceuticals firm's worldwide sales and profits for the year ended March 31 were 208.6 bil. yen and 6.3 bil. yen, not millions of yen; the dollar translations were correct in "The Pink Sheet" Aug. 28, p. 15. Sales were $ 1.6 bil. and earnings totaled $ 47.6 mil. Also, the calcium channel blocker nilvadipine, launched by the firm in Japan in April as Nivadil, was originally developed by Fujisawa, not Lederle.
You may also be interested in...
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.
Under an extensive COVID-19 plan and executive order signed on 21 January, the US president explained how he’ll beef up testing and manufacturing of medtech to fight the virus.